<DOC>
	<DOCNO>NCT02160275</DOCNO>
	<brief_summary>In previous study , test feasibility bi-hormonal close loop system . This system automate control blood glucose patient type 1 diabetes test clinical research center well home patient . Glucose control automate closed loop control comparable patient-managed open loop control . The closed loop system develop miniaturize ( backpack smartphone size ) order interfere little possible daily patient life . The aim trial ass efficacy new prototype home patient . It hypothesize close loop system provide well glucose control standard open loop therapy .</brief_summary>
	<brief_title>Algorithm Control Postprandial , Post Exercise Night Glucose Excursions Portable Closed Loop Format</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Diagnosed diabetes mellitus type 1 Treated insulin pump therapy minimum 6 month Age 18 75 year Willing able sign inform consent Impaired awareness hypoglycemia ( score â‰¥ 4 ) accord Gold and/or Clarke questionnaire BMI &gt; 35 kg/m2 HbA1c &gt; 97 mmol/mol ( =11.0 % ) Use heparin , coumarin derivative oral corticosteroid Skin condition prohibit needle insertion Pregnancy and/or breastfeed Living alone close loop period ( patient may ask someone stay temporarily ) Any condition local investigator feel would interfere trial participation evaluation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Artificial pancreas</keyword>
	<keyword>Bi-hormonal close loop</keyword>
	<keyword>Diabetes Type 1</keyword>
</DOC>